Calidi (CLDI) Director George Peoples Receives Stock Option Award

What Happened George Peoples, a director of Calidi Biotherapeutics, was issued a non‑qualified stock option grant on August 17, 2026 to purchase 4,000 shares of Calidi common stock. The options carry an exercise price of $1.36 per share (the closing price on the grant date) and were reported as a derivative award (transaction code A). There was no cash purchase by the insider at grant (reported acquisition value $0); the options were granted as part of the issuer’s non‑employee director compensation and issued under the 2023 Equity Incentive Plan.

Key Details

• Transaction date: August 17, 2026 (Form 4 filed August 19, 2026).
• Security: Non‑qualified stock options to purchase 4,000 shares; exercise price $1.36/share.
• Vesting: 1/12th per month over one year beginning on the grant date (fully vested after 12 months).
• Consideration: Reported as an award/derivative (no cash paid at grant).
• Plan/authority: Granted under the Issuer’s non‑employee director compensation policy and 2023 Equity Incentive Plan.
• Shares owned after transaction: Filing does not specify total common shares owned post‑grant here; footnote clarifies this grant does not include previously granted options.

Context This was an option grant (compensation) rather than a market purchase or sale — it does not represent an immediate cash investment or sale by the director. Options vest monthly over a year; they must be exercised (and possibly sold) later for any cash value to be realized. The filing appears timely (filed within the normal Form 4 reporting window).